Mitsuishi K, Umeno T, Tanaka S, Kimura H, Fuchino Y, Tomita A, Ikeda S
First Dept. of Surgery, School of Medicine, Fukuoka University.
Gan To Kagaku Ryoho. 1997 Jul;24(9):1119-24.
The subjects were 39 patients with gastric cancer and 44 patients with colorectal cancer divided into a group administered 400 mg/day of UFT orally for 2 weeks preoperatively (UFT group) and a group administered 400 mg/day of UFT as well as 40 mg/m2 (i.v.) of cisplatin (CDDP) by drip infusion once concomitantly (UFT + CDDP group). The thymidylate synthase (TS) inhibitory rate was measured in resected specimens and lymph nodes, and the concomitant effects of UFT and CDDP were investigated.
研究对象为39例胃癌患者和44例结直肠癌患者,分为术前2周口服400mg/天优福定的组(优福定组)和同时口服400mg/天优福定并静脉滴注40mg/m²顺铂(CDDP)一次的组(优福定+顺铂组)。在切除标本和淋巴结中测量胸苷酸合成酶(TS)抑制率,并研究优福定和顺铂的协同作用。
1)两组肿瘤组织中的TS抑制率无显著差异。2)在胃癌患者中,优福定+顺铂组转移淋巴结的TS抑制率高于优福定组(p<0.05)。在优福定+顺铂组中,胃癌或结直肠癌患者转移淋巴结的TS抑制率显著高于未转移淋巴结(胃癌p<0.05,结直肠癌p<0.05)。这些结果表明,优福定和顺铂联合使用对转移淋巴结似乎比对原发性肿瘤灶更有效,尤其是在胃癌病例中。